Nurix Therapeutics (NRIX) AI Stock Analysis

• Market Cap: $830.24M
• Dividend Yield: N/A
• Average Volume (3M): 1.12M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.15
• Revenue Growth: 48.32%
• EPS Growth: -1.91%
• Country: US
• Employees: 286
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.03
• Shares Outstanding: 76,449,356
• 10 Day Avg. Volume: 1,243,621
• 30 Day Avg. Volume: 1,119,140
• PEG Ratio: -0.88
• Price to Book (P/B): 2.82
• Price to Sales (P/S): 27.21
• P/FCF Ratio: -8.16
• Enterprise Value/Market Cap: 0.50
• Enterprise Value/Revenue: 4.94
• Enterprise Value/Gross Profit: 5.26
• Enterprise Value/Ebitda: -1.74
• 1Y Price Target: $27.45
• Price Target Upside: 152.76% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 11

• Rating: 49 Neutral
• Price Target: $9.50 ▼(-12.52% Downside)

Nurix Therapeutics' overall stock score is primarily impacted by its financial performance, which highlights strong gross margins but significant challenges in profitability and cash flow management. Technical analysis shows mixed signals with short-term bullish momentum but longer-term bearish trends. The negative P/E ratio further weighs on the valuation, reflecting ongoing financial losses.

Positive Factors

Innovative Drug Pipeline

Nurix's focus on innovative therapies, including pivotal studies for cancer and autoimmune diseases, highlights its potential to establish new treatment standards, enhancing long-term growth prospects.

Strategic Partnerships

Collaborations with major pharmaceutical companies like Gilead and Sanofi provide Nurix with resources and expertise, supporting its R&D efforts and enhancing its market position.

Strong Gross Margins

High gross margins indicate effective cost management, which can support profitability as the company scales and potentially improves its financial stability.

Negative Factors

Profitability Challenges

Ongoing profitability issues and declining revenue growth reflect challenges in achieving financial stability, which could hinder long-term business sustainability.

Cash Flow Management

Challenges in cash flow management may limit Nurix's ability to fund operations and invest in growth opportunities, impacting its long-term financial health.

Revenue Miss

Significant revenue miss against expectations suggests potential issues in market execution or product adoption, which could affect future revenue growth and investor confidence.

Nurix Therapeutics Business Overview & Revenue Model

Company Description

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.

How the Company Makes Money

Nurix Therapeutics generates revenue primarily through strategic partnerships and collaborations with larger pharmaceutical companies, which often involve upfront payments, milestone payments, and royalties based on future sales of drugs developed from their technology. The company also engages in research and development agreements, which can provide additional funding. Milestone payments are tied to the achievement of specific development goals, such as advancing a drug candidate into clinical trials or obtaining regulatory approval. Furthermore, if any of their drug candidates successfully reach the market, Nurix stands to benefit from royalties on sales, creating a sustainable revenue stream linked to the commercial success of its innovative therapies.

Nurix Therapeutics Financial Statement Overview

Summary

Nurix Therapeutics demonstrates strong gross margins and low leverage, but struggles with profitability and cash flow management. The company faces challenges in achieving revenue growth and improving operational efficiency, which are critical for future financial stability.

Income Statement

Nurix Therapeutics shows a strong gross profit margin of 90.44% in TTM, indicating effective cost management. However, the company faces significant challenges with negative net profit margins and declining revenue growth, reflecting ongoing profitability issues.

Balance Sheet

The company maintains a low debt-to-equity ratio of 0.12 in TTM, suggesting conservative leverage. However, the negative return on equity highlights inefficiencies in generating returns from shareholders' investments.

Cash Flow

Nurix Therapeutics has a positive free cash flow to net income ratio, indicating some efficiency in cash generation relative to net income. However, the negative operating cash flow and free cash flow growth suggest ongoing cash management challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	83.69M	54.55M	76.99M	38.63M	29.75M	17.82M
Gross Profit	78.69M	38.12M	63.33M	27.82M	23.67M	-48.67M
EBITDA	-238.12M	-196.60M	-141.41M	-173.06M	-111.80M	-62.80M
Net Income	-244.78M	-193.57M	-143.95M	-180.36M	-117.19M	-43.24M
Balance Sheet
Total Assets	522.47M	669.34M	355.60M	416.76M	476.77M	396.34M
Cash, Cash Equivalents and Short-Term Investments	428.83M	609.58M	287.91M	309.14M	295.72M	281.15M
Total Debt	56.49M	28.30M	30.61M	11.96M	13.04M	0.00
Total Liabilities	150.22M	142.35M	155.10M	113.06M	134.47M	106.07M
Stockholders Equity	372.25M	526.99M	200.49M	303.70M	342.30M	290.27M
Cash Flow
Free Cash Flow	-241.36M	-181.86M	-89.77M	-172.05M	-90.03M	-4.63M
Operating Cash Flow	-230.38M	-172.58M	-81.36M	-159.81M	-84.36M	-80.00K
Investing Cash Flow	6.69M	-257.71M	68.30M	27.20M	-108.25M	-254.40M
Financing Cash Flow	203.16M	485.67M	3.22M	117.19M	153.88M	339.02M

Nurix Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 10.86
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NRIX, the sentiment is Neutral. The current price of 10.86 is above the 20-day moving average (MA) of 9.12, above the 50-day MA of 9.57, and below the 200-day MA of 12.66, indicating a neutral trend. The MACD of 0.17 indicates Negative momentum. The RSI at 52.87 is Neutral, neither overbought nor oversold. The STOCH value of 75.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NRIX.

Nurix Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RLAY	55 Neutral	$1.05B	―	-46.24%	―	-76.27%	22.77%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VIR	49 Neutral	$839.06M	―	-46.22%	―	-75.91%	-12.11%
NRIX	49 Neutral	$830.24M	―	-65.35%	―	48.32%	-1.91%
ARVN	48 Neutral	$704.07M	―	-35.41%	―	―	―
TERN	45 Neutral	$722.84M	―	-35.02%	―	―	20.37%

Nurix Therapeutics Corporate Events

Nurix Therapeutics to Discuss Bexobrutideg Developments

Nurix Therapeutics announced plans to meet with securities analysts and investors starting September 3, 2025, to discuss updates on their clinical development plans for bexobrutideg. This drug is being tested in a Phase 1 trial and has shown potential in treating B cell malignancies by overcoming resistance mutations and crossing the blood-brain barrier. The announcement highlights the company’s strategic focus on advancing treatments for unmet medical needs, potentially impacting its market positioning and offering significant implications for stakeholders.

Nurix Therapeutics Announces Leadership Change in Committee

On August 19, 2025, Nurix Therapeutics announced that Lori A. Kunkel, M.D., would resign from her position as a Class III director and chair of the Clinical and Commercialization Committee, effective September 1, 2025. Her resignation was not due to any disagreements with the company. In response, the board appointed Roy D. Baynes to take over as chair of the Clinical and Commercialization Committee, also effective September 1, 2025.

Nurix Therapeutics Announces Positive Phase 1 Trial Results

On June 12, 2025, Nurix Therapeutics announced positive clinical data from its Phase 1 trial of bexobrutideg (NX-5948) at the European Hematology Association Congress. The data showed an objective response rate of 80.9% in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and 84.2% in patients with Waldenström macroglobulinemia (WM), with bexobrutideg demonstrating a favorable safety profile and potential as a treatment for patients with high unmet medical needs. The company plans to initiate pivotal trials in 2025, reinforcing its scientific leadership in targeted protein degradation.